New Search

If you are not happy with the results below please do another search

Search
Generic filters

50 search results for:

34

Evoke continues to build creative powerhouse in North America with integration of Evoke Giant

Evoke, a leading global health and wellness agency, announced the integration with San Francisco-based Evoke Giant to build a seamless North American client partner. The integration formally merges the two agencies while retaining the ability to service clients independently across the United States.

35

U.S. FDA limits use of Regeneron, Lilly COVID-19 antibody treatments

The U.S. health regulator revised on Jan. 24 the emergency use authorizations for COVID-19 antibody treatments from Regeneron and Eli Lilly to limit their use, as the drugs are unlikely to work against the Omicron coronavirus variant.

37

Mammoth Biosciences Receives FDA Emergency Use Authorization for First CRISPR-based High-Throughput COVID-19 Test

The U.S. Food and Drug Administration granted Emergency Use Authorization for Mammoth Biosciences Inc.’s DETECTR BOOST SARS-CoV-2 Reagent Kit, a first of its kind high-throughput solution that combines the power of CRISPR with laboratory automation for SARS-CoV-2 testing.

38

Omicron survives longer on plastic, skin than prior variants; nose swabbing found best for rapid tests

The Omicron variant can survive longer than earlier versions of the coronavirus on plastic surfaces and human skin, Japanese researchers found in laboratory tests. Additionally, new research shows users of rapid antigen tests to detect COVID-19 should swab their nostrils as directed by the manufacturer and not swab the throat or cheek instead.

39

Sinovac regimen gets strong boost from Pfizer, AstraZeneca or J&J COVID shots – study

A third booster dose of a COVID-19 vaccine made by AstraZeneca, Pfizer-BioNTech or Johnson & Johnson increases antibody levels significantly in those who have previously received two doses of Sinovac’s CoronaVac shot, a study has found.

40

Six Companies Hit the Clinic with Innovative Therapeutic Candidates

TScan Therapeutics secured clearance from the U.S. Food and Drug Administration for the company’s investigational new drug application to assess TSC-100 in treating patients with hematologic malignancies undergoing allogeneic hematopoietic cell transplantation (HCT).